Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation.

Altimari A, Gruppioni E, Fiorentino M, Petraroli R, Pinna AD, Petropulacos K, Ridolfi L, Costa AN, Grigioni WF, Grigioni AD.

Diagn Mol Pathol. 2005 Mar;14(1):34-8.

PMID:
15714062
2.

Molecular techniques for identifying HCC origin and biology after orthotopic liver transplantation.

Mas VR, Maluf DG, Dumur CI, Archer KJ, Yanek K, Jackson-Cook C, Fisher RA.

Diagn Mol Pathol. 2006 Jun;15(2):90-4.

PMID:
16778589
3.

Donor origin of de novo hepatocellular carcinoma in hepatic allografts.

Flemming P, Tillmann HL, Barg-Hock H, Kleeberger W, Manns MP, Klempnauer J, Kreipe HH.

Transplantation. 2003 Dec 15;76(11):1625-7.

PMID:
14702536
4.

Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.

Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P, Klein KM, Chun H, Marvin M, Rozenblit G, Rodriguez-Davalos M, Sheiner PA.

Ann Surg Oncol. 2008 May;15(5):1383-91. doi: 10.1245/s10434-008-9851-z. Epub 2008 Mar 5.

PMID:
18320284
5.

Donor origin of de novo hepatocellular carcinoma in hepatic allografts.

Flemming P, Tillmann HL, Barg-Hock H, Kleeberger W, Manns MP, Klempnauer J, Kreipe HH.

Transplantation. 2003 Sep 15;76(5):871-3.

PMID:
14501871
6.

Hepatocellular carcinoma in children and effect of living-donor liver transplantation on outcome.

Arikan C, Kilic M, Nart D, Ozgenc F, Ozkan T, Tokat Y, Yagci RV, Aydogdu S.

Pediatr Transplant. 2006 Feb;10(1):42-7.

PMID:
16499586
7.

Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma.

Finkelstein SD, Marsh W, Demetris AJ, Swalsky PA, Sasatomi E, Bonham A, Subotin M, Dvorchik I.

Hepatology. 2003 Apr;37(4):871-9.

PMID:
12668980
8.

Intraoperative blood salvage during liver transplantation in patients with hepatocellular carcinoma: efficiency of leukocyte depletion filters in the removal of tumor cells.

Liang TB, Li DL, Liang L, Li JJ, Bai XL, Yu W, Wang WL, Shen Y, Zhang M, Zheng SS.

Transplantation. 2008 Mar 27;85(6):863-9. doi: 10.1097/TP.0b013e3181671f2e.

PMID:
18360269
9.

Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China.

Zhou J, Fan J, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Wang Z, Sun J, Xiao YS, He YF, Yang GH, Song K, Yuan Z, Wang YQ, Tang ZY.

Chin Med J (Engl). 2005 Apr 20;118(8):654-9.

PMID:
15899120
10.

Origin of hepatocellular carcinoma recurring after allotransplantation revealed by microsatellite analysis.

Pfeiffer H, Ortmann C, Klein A, Brinkmann B.

J Clin Pathol. 1997 Sep;50(9):792-4.

11.

Detection of circulating albumin-mRNA by RT-PCR does not indicate metastasizing hepatocellular carcinoma.

Leonhardt U, Ritzel U, Ottleben M, Vignoli A, Ramadori G.

Langenbecks Arch Chir. 1997;382(2):83-6.

PMID:
9128873
13.

Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population.

Wang P, Song W, Li H, Wang C, Shi B, Guo W, Zhong L.

Tumour Biol. 2015 Sep;36(10):7807-15. doi: 10.1007/s13277-015-3370-x. Epub 2015 May 6.

PMID:
25944162
14.

Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences.

Itano O, Ueda M, Kikuchi K, Hashimoto O, Hayatsu S, Kawaguchi M, Seki H, Aiura K, Kitajima M.

Oncogene. 2002 Jan 24;21(5):789-97.

15.

A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.

Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP.

Liver Transpl. 2005 Dec;11(12):1505-14.

16.

Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival.

Marsh JW, Finkelstein SD, Demetris AJ, Swalsky PA, Sasatomi E, Bandos A, Subotin M, Dvorchik I.

Liver Transpl. 2003 Jul;9(7):664-71.

17.

Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.

Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW.

Arch Surg. 2008 Feb;143(2):182-8; discussion 188. doi: 10.1001/archsurg.2007.39. Review.

PMID:
18283144
18.

Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation.

Kiyici M, Yilmaz M, Akyildiz M, Arikan C, Aydin U, Sigirli D, Nart D, Yilmaz F, Ozacar T, Karasu Z, Kilic M.

Transplant Proc. 2008 Jun;40(5):1511-7. doi: 10.1016/j.transproceed.2008.03.156.

PMID:
18589140
19.

Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.

Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST.

Mol Cell Proteomics. 2008 Feb;7(2):315-25. Epub 2007 Oct 14.

20.

MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation.

Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, Shen Y, Zhang M, Zheng S.

J Surg Oncol. 2007 Jul 1;96(1):62-8.

PMID:
17443726

Supplemental Content

Support Center